# US 2003/0229064 A1 · Method of treating cancer using dithiocarbamate derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0229064 A1
- Document ID: US20030229064A1
- Status: Published application
- Kind: A1
- Application number: 10/378,206
- Filed: 2003-03-03
- Published: 2003-12-11
- Earliest claimed: 1998-09-08
- Assignees: Charlotte-Mecklenburg Hospital Authority d/b/a Carolinas Medical Center
- Inventors: Thomas Preston Kennedy
- Web page: https://patentgrep.com/patent/US20030229064A1

## CPC

- A61K 33/24: Heavy metals; Compounds thereof
- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61K 31/325: Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof (thiurams A61K31/145)
- A61K 33/04: Sulfur, selenium or tellurium; Compounds thereof
- A61K 33/242: Gold; Compounds thereof
- A61K 33/243: Platinum; Compounds thereof
- A61K 33/245: Bismuth; Compounds thereof
- A61K 33/26: Iron; Compounds thereof
- A61K 33/30: Zinc; Compounds thereof
- A61K 33/32: Manganese; Compounds thereof
- A61K 33/34: Copper; Compounds thereof
- A61K 33/36: Arsenic; Compounds thereof
- A61K 33/38: Silver; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.

## Claims

### Claim 1

A method of treating cancer in humans and for sensitizing tumors to conventional cancer chemotherapy by blocking the P-glycoprotein membrane toxin extrusion pump and for sensitizing AIDS patients to anti-retroviral therapy by blocking the P-glycoprotein membrane toxin extrusion pump comprising administering a therapeutically effective amount of a dithiocarbamate thiolate an n of the formula:
7
wherein R2 and R3 are the same or different and represent hydrogen, and unsubstituted or substituted alkyl, akenyl, aryl, alkoxy, and heteroaryl groups; M is an alkali metal selected from the group consisting of from the group consisting of sodium, potassium, calcium, magnesium, barium, and lithium; and n is the valence of the alkali metal.

### Claim 2 (depends on 1)

The method according to claim 1 wherein said dithiocarbamate thiolate anion is in the form of a pharmaceutically acceptable salt.

### Claim 3 (depends on 1)

The method according to claim 1 wherein said dithiocarbamate thiolate anion is administered in a dosage of between about 125 to about 1000 mg per day of body weight.

### Claim 4 (depends on 1)

The method according to claim 1 wherein said dithiocarbamate thiolate anion is administered in a dosage of between about 250 to about 500 mg per day.

### Claim 5 (depends on 1)

The method according to claim 1 wherein said dithiocarbamate thiolate anion is administered parenterally.

### Claim 6 (depends on 1)

The method according to claim 1 wherein said dithiocarbamate thiolate anion is administered orally.

### Claim 7 (depends on 1)

The method according to claim 1 wherein said dithiocarbamate thiolate anion is administered in combination with a metal complex that includes a metal selected from the group consisting of arsenic, bismuth, cobalt, copper chromium, gallium, gold iron, manganese, nickel, silver, titanium, vanadium, selenium and zinc, and an anion of small molecular weight.

### Claim 8 (depends on 1)

The method according to claim 1 wherein said dithiocarbamate thiolate anion is administered in combination with a metal chelate that includes an ion selected from the group consisting of arsenic, bismuth, cobalt, copper chromium, gallium, gold iron, manganese, nickel, silver, titanium, vanadium, selenium and zinc.

### Claim 9 (depends on 7)

The method according to claim 7 wherein said metal complex is administered as a chelate with an organic anion.

### Claim 10 (depends on 9)

The method according to claim 9 wherein said organic anion selected from the group consisting of citrate, acetate, glyconate, glycinate, propionate and lactate.

### Claim 11 (depends on 1)

The method according to claim 1 wherein said dithiocarbamate thiolate anion is administered in combination with a metal chelate that includes an ion selected from the group consisting of arsenic, bismuth, cobalt, copper chromium, gallium, gold iron, manganese, nickel, silver, titanium, vanadium, selenium and zinc, and an anion of small molecular weight.

### Claim 12

A method of treating cancer in humans and for sensitizing tumors to conventional cancer chemotherapy by blocking the P-glycoprotein membrane toxin extrusion pump and for sensitizing AIDS patients to anti-retroviral therapy by blocking the P-glycoprotein membrane toxin extrusion pump comprising administering a therapeutically effective amount of a dithiocarbamate thiolate metal complex of the formula:
8
wherein R2 and R3 are the same or different and represent hydrogen, and unsubstituted or substituted alkyl, akenyl, aryl, alkoxy, and heteroaryl groups; M is a heavy metal selected from the group consisting of arsenic, bismuth, gallium, manganese, selenium, zinc, titanium, vanadium, chromium, iron, cobalt, nickel, copper, silver, silver, and gold; An is an anion selected from the group consisting of chloride, bromide, iodide, acetate and low molecular weight organic or inorganic pharmaceutically acceptable anions; n is the valence of the metal.

### Claim 13 (depends on 12)

The method according to claim 12 wherein said dithiocarbamate thiolate metal complex is in the form of a pharmaceutically acceptable salt.

### Claim 14 (depends on 12)

The method according to claim 12 wherein said dithiocarbamate thiolate metal complex is administered in a dosage of between about 125 to about 1000 mg per day of body weight.

### Claim 15 (depends on 12)

The method according to claim 12 wherein said dithiocarbamate thiolate metal complex is administered in a dosage of between about 250 to about 500 mg per day.

### Claim 16 (depends on 12)

The method according to claim 12 wherein said dithiocarbamate thiolate metal complex is administered parenterally.

### Claim 17 (depends on 12)

The method according to claim 12 wherein said dithiocarbamate thiolate anion is administered orally.

### Claim 18 (depends on 12)

The method according to claim 12 wherein said metal complex is administered separately as a chelate with an organic anion.

### Claim 19 (depends on 18)

The method according to claim 18 wherein said an organic anion is selected from the group consisting of citrate, acetate, glyconate, glycinate, propionate and lactate.

### Claim 20

A method of reducing hypoxic or ischemic damage to the cardiovascular system of a human comprising administering a therapeutically effective amount of a dithiocarbamate thiolate anion of the formula:
9
wherein R2 and R3 are the same or different and represent hydrogen, and unsubstituted or substituted alkyl, akenyl, aryl, alkoxy, and heteroaryl groups; M is an alkali metal selected from the group consisting of from the group consisting of sodium, potassium, calcium, magnesium, barium, and lithium; and n is the valence of the alkali metal.

### Claim 21 (depends on 20)

The method according to claim 20 wherein said dithiocarbamate thiolate anion is in the form of a pharmaceutically acceptable salt.

### Claim 22 (depends on 20)

The method according to claim 20 wherein said dithiocarbamate thiolate anion is administered in a dosage of between about 125 to about 1000 mg per day of body weight.

### Claim 23 (depends on 20)

The method according to claim 20 wherein said dithiocarbamate thiolate anion is administered in a dosage of between about 250 to about 500 mg per day for disulfiram.

### Claim 24 (depends on 20)

The method according to claim 20 wherein said dithiocarbamate thiolate anion is administered parenterally.

### Claim 25 (depends on 20)

The method according to claim 20 wherein said dithiocarbamate thiolate anion is administered orally.

### Claim 26 (depends on 20)

The method according to claim 20 wherein said dithiocarbamate thiolate anion is administered in combination with a metal complex that includes an ion selected from the group consisting of arsenic, bismuth, cobalt, copper chromium, gallium, gold iron, manganese, nickel, silver, titanium, vanadium, selenium and zinc.

### Claim 27 (depends on 26)

The method according to claim 26 wherein said metal complex is administered as a chelate with an organic anion.

### Claim 28 (depends on 27)

The method according to claim 27 wherein said an organic anion is selected from the group consisting of citrate, acetate, glyconate, glycinate, propionate and lactate.

### Claim 29 (depends on 20)

The method according to claim 20 wherein said dithiocarbamate thiolate anion is administered in combination with a metal chelate that includes an ion selected from the group consisting of arsenic, bismuth, cobalt, copper chromium, gallium, gold iron, manganese, nickel, silver, titanium, vanadium, selenium and zinc.

### Claim 30

A method of reducing hypoxic or ischemic damage to the cardiovascular system of a human comprising administering a therapeutically effective amount of a dithiocarbamate thiolate metal complex of the formula:
10
wherein R2 and R3 are the same or different and represent hydrogen, and unsubstituted or substituted alkyl, akenyl, aryl, alkoxy, and heteroaryl groups; M is a heavy metal selected from the group consisting of arsenic, bismuth, gallium, manganese, selenium, zinc, titanium, vanadium, chromium, iron, cobalt, nickel, copper, silver, silver, and gold; An is an anion selected from the group consisting of chloride, bromide, iodide, acetate and low molecular weight organic or inorganic pharmaceutically acceptable anions; n is the valence of the metal.

### Claim 31 (depends on 30)

The method according to claim 30 wherein said dithiocarbamate thiolate metal complex is in the form of a pharmaceutically acceptable salt.

### Claim 32 (depends on 30)

The method according to claim 30 wherein said dithiocarbamate thiolate metal complex is administered in a dosage of between about 125 to about 1000 mg per day of body weight.

### Claim 33 (depends on 30)

The method according to claim 30 wherein said dithiocarbamate thiolate metal complex is administered in a dosage of between about 250 to about 500 mg per day for disulfiram.

### Claim 34 (depends on 30)

The method according to claim 30 wherein said dithiocarbamate thiolate metal complex is administered parenterally.

### Claim 35 (depends on 30)

The method according to claim 30 wherein said dithiocarbamate thiolate metal complex is administered orally.

### Claim 36 (depends on 30)

The method according to claim 30 wherein said metal complex is administered separately as a chelate with an organic anion.

### Claim 37 (depends on 36)

The method according to claim 36 wherein said an organic anion is selected from the group consisting of citrate, acetate, glyconate, glycinate, propionate and lactate.

### Claim 38

A method for treating asthma or arthritis in humans comprising administering a therapeutically effective amount of a dithiocarbamate thiolate anion of the formula:
11
wherein R2 and R3 are the same or different and represent hydrogen, and unsubstituted or substituted alkyl, akenyl, aryl, alkoxy, and heteroaryl groups; M is an alkali metal selected from the group consisting of from the group consisting of sodium, potassium, calcium, magnesium, barium, and lithium; and n is the valence of the alkali metal.

### Claim 39 (depends on 38)

The method according to claim 38 wherein said dithiocarbamate thiolate anion is in the form of a pharmaceutically acceptable salt.

### Claim 40 (depends on 38)

The method according to claim 38 wherein said dithiocarbamate thiolate anion is administered in a dosage of between about 125 to about 1000 mg per day of body weight.

### Claim 41 (depends on 38)

The method according to claim 38 wherein said dithiocarbamate thiolate anion is administered in a dosage of between about 250 to about 500 mg per day for disulfiram.

### Claim 42 (depends on 38)

The method according to claim 38 wherein said dithiocarbamate thiolate anion is administered parenterally.

### Claim 43 (depends on 38)

The method according to claim 38 wherein said dithiocarbamate thiolate anion is administered orally.

### Claim 44 (depends on 38)

The method according to claim 38 wherein said dithiocarbamate thiolate anion is administered in combination with a metal complex that includes an ion selected from the group consisting of arsenic, bismuth, cobalt, copper chromium, gallium, gold iron, manganese, nickel, silver, titanium, vanadium, selenium and zinc.

### Claim 45 (depends on 44)

The method according to claim 44 wherein said metal complex is administered separately as a chelate with an organic anion.

### Claim 46 (depends on 45)

The method according to claim 45 wherein said an organic anion is selected from the group consisting of citrate, acetate, glyconate, glycinate, propionate and lactate.

### Claim 47 (depends on 38)

The method according to claim 38 wherein said dithiocarbamate thiolate anion is administered in combination with a metal chelate that includes an ion selected from the group consisting of arsenic, bismuth, cobalt, copper chromium, gallium, gold iron, manganese, nickel, silver, titanium, vanadium, selenium and zinc.

### Claim 48

A method for treating asthma or arthritis in humans comprising administering a therapeutically effective amount of a dithiocarbamate thiolate anion of the formula:
12
wherein R2 and R3 are the same or different and represent hydrogen, and unsubstituted or substituted alkyl, akenyl, aryl, alkoxy, and heteroaryl groups; M is a heavy metal selected from the group consisting of arsenic, bismuth, gallium, manganese, selenium, zinc, titanium, vanadium, chromium, iron, cobalt, nickel, copper, silver, silver, and gold; An is an anion selected from the group consisting of chloride, bromide, iodide, acetate and low molecular weight organic or inorganic pharmaceutically acceptable anions; n is the valence of the metal.

### Claim 49 (depends on 48)

The method according to claim 48 wherein said dithiocarbamate thiolate metal complex is in the form of a pharmaceutically acceptable salt.

### Claim 50 (depends on 48)

The method according to claim 48 wherein said dithiocarbamate thiolate metal complex is administered in a dosage of between about 125 to about 1000 mg per day of body weight.

### Claim 51 (depends on 48)

The method according to claim 48 wherein said dithiocarbamate thiolate metal complex is administered in a dosage of between about 250 to about 500 mg per day for disulfiram.

### Claim 52 (depends on 48)

The method according to claim 48 wherein said dithiocarbamate thiolate metal complex is administered parenterally.

### Claim 53 (depends on 48)

The method according to claim 48 wherein said dithiocarbamate thiolate metal complex is administered orally.

### Claim 54 (depends on 48)

The method according to claim 48 wherein said metal complex is administered separately as a chelate with an organic anion.

### Claim 55 (depends on 54)

The method according to claim 54 wherein said an organic anion is selected from the group consisting of citrate, acetate, glyconate, glycinate, propionate and lactate.
